A phase II trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC).
Jeong Heo
Consultant or Advisory Role - Jennerex Biotherapeutics (U)
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Mong Cho
Consultant or Advisory Role - Jennerex Biotherapeutics (U)
Tae-Ho Hwang
Consultant or Advisory Role - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Research Funding - Jennerex Biotherapeutics
Chang Won Kim
Stock Ownership - Sillajen
Ung Bae Jeon
No relevant relationships to disclose
Hyun Young Woo
No relevant relationships to disclose
Ki Tae Yoon
No relevant relationships to disclose
Jun Woo Lee
No relevant relationships to disclose
James Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Theresa Hickman
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Kara S DuBois
Employment or Leadership Position - Jennerex Biotherapeutics
Consultant or Advisory Role - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Lara Longpre
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Richard H. Patt
Consultant or Advisory Role - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics